Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis
dc.contributor.author | Kühl, Melf-Jakob | |
dc.contributor.author | Gondwe, Thandile | |
dc.contributor.author | Dhabangi, Aggrey | |
dc.contributor.author | Kwambai, Titus K. | |
dc.contributor.author | Mori, Amani T. | |
dc.contributor.author | Opoka, Robert | |
dc.contributor.author | John, C. Chandy | |
dc.contributor.author | Idro, Richard | |
dc.contributor.author | ter Kuile, Feiko O. | |
dc.contributor.author | Phiri, Kamija S. | |
dc.contributor.author | Robberstad, Bjarne | |
dc.contributor.department | Pediatrics, School of Medicine | |
dc.date.accessioned | 2024-06-05T15:42:44Z | |
dc.date.available | 2024-06-05T15:42:44Z | |
dc.date.issued | 2022-10-01 | |
dc.description.abstract | Background: Children hospitalised with severe anaemia in malaria-endemic areas are at a high risk of dying or being readmitted within six months of discharge. A trial in Kenya and Uganda showed that three months of postdischarge malaria chemoprevention (PDMC) with monthly dihydroartemisinin-piperaquine (DP) substantially reduced this risk. The World Health Organization recently included PDMC in its malaria chemoprevention guidelines. We conducted a cost-effectiveness analysis of community-based PDMC delivery (supplying all three PDMC-DP courses to caregivers at discharge to administer at home), facility-based PDMC delivery (monthly dispensing of PDMC-DP at the hospital), and the standard of care (no PDMC). Methods: We combined data from two recently completed trials; one placebo-controlled trial in Kenya and Uganda collecting efficacy data (May 6, 2016 until November 15, 2018; n=1049), and one delivery mechanism trial from Malawi collecting adherence data (March 24, 2016 until October 3, 2018; n=375). Cost data were collected alongside both trials. Three Markov decision models, one each for Malawi, Kenya, and Uganda, were used to compute incremental cost-effectiveness ratios expressed as costs per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analyses were performed to account for uncertainty. Findings: Both PDMC strategies were cost-saving in each country, meaning less costly and more effective in increasing health-adjusted life expectancy than the standard of care. The estimated incremental cost savings for community-based PDMC compared to the standard of care were US$ 22·10 (Malawi), 38·52 (Kenya), and 26·23 (Uganda) per child treated. The incremental effectiveness gain using either PDMC strategy varied between 0·3 and 0·4 QALYs. Community-based PDMC was less costly and more effective than facility-based PDMC. These results remained robust in sensitivity analyses. Interpretation: PDMC under implementation conditions is cost-saving. Caregivers receiving PDMC at discharge is a cost-effective delivery strategy for implementation in malaria-endemic southeastern African settings. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Kühl MJ, Gondwe T, Dhabangi A, et al. Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis. EClinicalMedicine. 2022;52:101669. Published 2022 Oct 1. doi:10.1016/j.eclinm.2022.101669 | |
dc.identifier.uri | https://hdl.handle.net/1805/41232 | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | |
dc.relation.isversionof | 10.1016/j.eclinm.2022.101669 | |
dc.relation.journal | eClinicalMedicine | |
dc.rights | Attribution 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | PMC | |
dc.subject | Adherence | |
dc.subject | Children under five years of age | |
dc.subject | Cost-effectiveness analysis | |
dc.subject | Dihydroartemisinin-piperaquine | |
dc.subject | Economic evaluation | |
dc.subject | Intermittent preventive therapy | |
dc.subject | Kenya | |
dc.subject | Malaria prophylaxis | |
dc.subject | Malawi | |
dc.subject | Post-discharge | |
dc.subject | Preschool children | |
dc.subject | Severe anaemia | |
dc.subject | Sub-Saharan Africa | |
dc.subject | Uganda | |
dc.subject | Malaria chemoprevention | |
dc.subject | Malaria prevention | |
dc.title | Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis | |
dc.type | Article |